Catalog No.: PC-42691Not For Human Use, Lab Use Only.
Rislenemdaz (MK-0657, CERC-301) is a potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively, with no off-target activity.
Rislenemdaz (MK-0657, CERC-301) is a potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively, with no off-target activity.
Rislenemdaz (MK-0657, CERC-301) inhibits calcium influx into agonist‐stimulated NMDA‐GluN1a/GluN2B L(tk‐) cells with IC50 of 3.6 nM, with no effect on GluN2A up to 30 uM.
Rislenemdaz (MK-0657, CERC-301) significantly decreases immobility frequency and increases swimming behavior in acute depression models.
